Consun Pharma Sets March Board Meeting to Approve 2025 Results and Consider Dividend

The latest announcement is out from Consun Pharmaceutical Group Ltd. ( (HK:1681) ).

Consun Pharmaceutical Group Limited has scheduled a board meeting for 26 March 2026 to review and approve its audited consolidated financial statements for the year ended 31 December 2025 and to clear the related results announcement for publication under Hong Kong listing rules. The board will also consider proposing a final dividend, address arrangements for the upcoming annual general meeting and handle other corporate matters, signaling routine governance steps that may influence shareholder returns and disclosure timelines.

The meeting agenda underscores the company’s adherence to regulatory requirements and its ongoing communication with investors through formal approval of annual results. Any decision on a final dividend at this session will be closely watched by shareholders as an indicator of the group’s financial health and capital allocation priorities for the past financial year.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

More about Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company based in the Cayman Islands, engaged in the development, manufacturing and sale of pharmaceutical products. The group operates through various subsidiaries and is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical corporate governance structure for a listed healthcare firm in the region.

Average Trading Volume: 1,386,166

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.62B

Learn more about 1681 stock on TipRanks’ Stock Analysis page.